National and Kapodistrian University of Athens
Μελέτη μοριακών μηχανισμών απόκρισης του κυττάρου στις βλάβες του DNA που επάγονται από αλκυλιωτικούς παράγοντες
Abstract
dc:descriptionIntroduction: It is obvious that DNA repair plays an important role in the resistance to chemotherapeutic agents with genotoxic action. In deed, it has been previously shown that, in peripheral blood mononuclear cells (PBMC) of multiple myeloma (MM) patients treated with melphalan, accumulation of DNA adducts in the p53 gene correlates with better therapeutic response, and that repair in different genes correlated with the gene transcriptional activity and the degree of local chromatin condensation Purpose: One of the major subjects of my thesis is to investigate the molecular mechanistic basis of melphalan adduct repair and the relationship between the local chromatin structure, the transcriptional activity and DNA repair. The general goal of this study is to find a molecular biomarker for predicting M.M. patient response to chemotherapy with alkylating agents and its clinical application. Materials and Methods: For this purpose, we used (a) four primary human fibroblast cell lines (VH25: GGR+/TCR+; CSB: GGR+/TCR-; XPC: GGR-/TRC+; XP-A: GGR-/TCR-) with varying Nucleotide Excision Repair activity (NER) (b) the human cell line HepG2 and (c) peripheral blood mononuclear cells (PBMC) received from healthy volunteers and M.M. patients. The levels of DNA damage formation/repair induced by in vitro exposure to melphalan were measured using Southern blot analysis and the quantitative PCR assay. We focused our studies on the repair efficiency in different genomic loci corresponding to the b-actin, p53, N-ras, and d-globin genes. The steady-state RNA levels of these genes were measured by RNA slot-blot analysis whereas transcription rates were measured using a run-off transcription assay. To analyze chromatin condensation, nuclei from untreated cells were subjected to micrococcal nuclease digestion. Results: In NER–deficient cells, adducts accumulated to similar levels in all four genes indicating that the adduct formation is the same at these genomic regions. Adducts were found to be substrates for both global genome repair (GGR) and transcription-coupled repair (TCR), with TCR being less efficient than GGR. No strand-specific repair was found in GGR+/TCR+ cells, implying that in normal cells GGR dominated. The repair efficiency in different gene loci varied in a qualitatively and quantitatively similar way in both GGR-deficient and TCR-deficient backgrounds and correlated with transcriptional activity and local chromatin condensation. Additionally, adducts were lost over two sharply demarcated phases: a rapid phase resulting in the removal within 1 hour of up to ~80% of the adducts, and a subsequent phase with t1/2 36 to 48 hours. To further investigate the extensive repair occurring during the 1-hour melphalan treatment, cells were treated with a higher concentration of melphalan (100 μg/ml) for only 5 minutes and, subsequently, repair was followed for up to 2 hours. The results confirmed that, in the absence of NER, similar adduct levels accumulated in all four genes, whereas in all repair proficient backgrounds, a substantial fraction (~60–75%) of the adducts formed underwent rapid repair. To further elucidate the molecular mechanism of region specific NER, we have measured the repair efficiency and the chromatin structure, along the length of the two transcribed p53 and N-ras genes, and the silent d-globin gene, against different repair backgrounds. In NER-deficient XP-A cells, similar levels of adducts were found in all fragments examined, indicating uniform distribution of DNA damage. In both, repair-proficient CS-B and XP-C cells, faster repair was observed in regions inside the transcribed N-ras and p53 genes, compared to regions on both sides outside of the genes, while no such difference was observed for the inactive d-globin gene. Moreover, very fast adduct repair on the transcribed strand of the active genes was seen immediately downstream of the transcription start site, together with a steeply decreasing gradient of repair efficiency along the gene towards the 3′-end. In all cells analyzed, the above variation in DNA repair efficiency was paralleled exactly by the variation in the degree of local chromatin condensation, more relaxed chromatin being associated with faster repair. Similar results were obtained using peripheral blood mononuclear cells from healthy volunteers and Multiple Myeloma patients, suggesting that the existence of a repair gradient along transcribed genes may be a universal phenomenon. Interestingly, the difference in the repair activity between responders and non-responders becomes maximal at the 5′-end of the N-ras gene, decreasing towards the 3′-end of the gene. As for the d-globin gene, an induction of the transcription activity, a higher “looseness” of the local chromatin structure and an increase in the repair efficiency was observed specifically in MM patients who did not respond to melphalan therapy.Although our data showed that DNA damage induced by alkylating anticancer drugs may serve as a biomarker predictive of patient therapeutic response, the assays used for the measurement of gene specific DNA repair are fairly time-consuming, and require complex procedures such as Southern transfer and hybridization. Therefore, a more rapid and convenient methodology of wider applicability, suitable for application in a clinical context, is highly desirable. Thus, as a next step of this thesis was the development and clinical application in MM of a gene-specific, quantitative method for measuring DNA damage formation/repair following exposure to anticancer drugs inducing bulky adducts. Using the stable cell line HepG2, we found the appropriate conditions in order the extent of PCR amplification to be conversely proportional to the treatment concentrations of melphalan, implying dose-related inhibition by the DNA adducts formed. The adduct levels measured by Q-PCR were identical to the levels of interstrand cross-links (ICL) measured by Southern blot analysis, suggesting that this assay measures only melphalan-induced ICLs. Application of the Q-PCR assay to in vitro-treated human blood samples from MM patients taken prior to ASCT showed that significantly greater gene-specific damage was found in the responders group compared to non-responders [176.8+67.3 adducts/106 nucleotides (range 41.0 to 273.0) for responders and 65.1+39.4 adducts/106 nucleotides (range 22.0 to 135.0) for non-responders, p=0.002]. Conclusions: One of the major findings of this study is that in human normal cells the melphalan adducts are repaired almost exclusively by the GGR mechanism. Additionally, our study suggests that the DNA repair efficiency, the transcriptional activity and the local chromatin structure in different gene loci are tightly connected, and could be used as molecular markers to select those patients with MM who are more likely to benefit from HDM therapy. Last but not least, using the Q-PCR methodology, it is feasible to measure gene-specific damage formation/repair in a readily accessible biological material such as PBMC from humans exposed to anticancer drugs, which induce bulky adducts, and to examine, at the level of individual patient, the relationship between the induction/repair of cytotoxic DNA damage and the clinical outcome.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Episkopou, Harikleia
- Επισκόπου, Χαρίκλεια
Subjects
dc:subject × 20- Μελφαλάνη
- Επιδιόρθωση του DNA
- Πολλαπλούν μυέλωμα
- Επιδιόρθωση με εκτομή νουκλεοτιδίου
- Κλινική απόκριση
- Βιολογικοί δείκτες
- Χημειοθεραπεία
- Βλάβες του DNA
- Melphalan
- DNA repair
- Multiple myeloma
- Nucleotide excision repair
- Clinical response
- Biomarkers
- Chemotherapy
- DNA adducts
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/29478